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Introduction
 The diagnosis of aplastic anemia (AA) is 
sometimes difficult solely based on character-
istics of pancytopenia and hypocellular bone 
marrow. The pathogenetic characteristics of 
AA, myelodysplastic syndrome (MDS), and 
acute myelogeneous leukemia (AML) partly 
overlap, and clonal hematopoiesis has been 
observed in these disorders.???? There are sev-
eral reports of the development of MDS and 
leukemia during the clinical course of AA, 
especially in cases treated with immunosup-
pressants or G-CSF.???? The concepts of hypo-
plas tic leukemia or hypoplastic MDS are also 
recognized.??10? These share morphological 
characteristics of pancytopenia, bone mar-
row hypocellularity, and dysplasia or a low 
percentage of leukemic hematopoietic cells. 
Cytogenetic abnormalities have been re-
ported in patients with otherwise typical AA, 
involving chromosome 7 such as monosomy 
7 or trisomy 8.11? Leukopenia is present more 
commonly in patients with acute promyelo-
cytic leukemia (APL); however the bone mar-
row is usually hypercellular.12? Hypoplastic 
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Abstract?A 62-year-old male developed pancytopenia due to severe hypocellular 
marrow. He was initially diagnosed with aplastic anemia (AA), and was treated 
with antilymphocyte globulin (ATG), cyclosporine (CyA), and granulocyte colony-
stimulating factor (G-CSF). However, 3 days after starting the therapy, the leukocyte 
count increased abruptly and the bone marrow became markedly hypercellular with 
hypergranulated promyelocytes. Cytogenetic analysis demonstrated t(15;17)(q22;q12) 
and promyleocytic leukemia/retinoic acid receptor-α (PML/RAR-α) fusion genes on 
employing interphase fluorescence in situ-hybridization (FISH) and nested PCR. He 
was diagnosed with acute promyelocytic leukemia (APL). He was initially treated 
with all-trans retinoic acid (ATRA) for 60 days. Hypergranulated promyelocytes 
decreased, and anemia and thrombocytopenia improved; however, neutropenia and 
dysplastic cells markedly remained, while the bone marrow retained its hypocellu-
larity. Finally complete hematological and cytogenetic remissions were achieved. He 
was subsequently treated with 3 courses of reduced doses of chemotherapeutic agents 
consisting of cytosine arabinoside (Ara-C) and alternating regimens of mitoxantrone 
(MIT), daunorubicin (DNR), and idarubicin (IDR) as consolidation chemotherapy. 
However, bone marrow cellularity remained hypocellular, although peripheral blood 
counts returned to normal. 
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leukemia usually occurs in AML, and is rare 
in APL.??10? We encountered a case of APL 
who initially presented with pancytopenia 
and hypocellular marrow and was initially 
diagnosed with AA, which was successfully 
treated with all-trans retinoic acid (ATRA) 
and subsequent chemotherapy.
Case report
 A 62-year-old male who complained of pur-
pura of the lower extremities was pointed 
out to have pancytopenia in another hospital, 
and was referred to us. Laboratory data on 
admission are shown in Table 1. CBC dem-
onstrated severe pancytopenia, and a bone 
marrow aspiration smear demonstrated 
markedly hypocellular marrow (Fig. 1). 
Cytogenetic analysis of bone marrow cells 
was not performed at this time. Magnetic 
resonance imaging (MRI) of the bone demon-
strated hypocellularity of the bone marrow. 
Hemostatic findings were normal. Based 
on these data, diagnosis of aplastic anemia 
(AA) was made. Paroxysmal nocturnal he-
CBC Bone Marrow Markedly Hypocellular
?RBC (x104/μl) 321 ?Myeloblasts (%) 4.0 
?Hb (g/dl) 10.2 ?Promyelocytes (%) 7.0 
?Ht (%) 29.7 ?N Myelocytes (%) 2.0 
?Ret (%) 1.2 ?N Metamyelocytes (%) 1.0 
?Platelets (x104/μl) 6.7 ?N Bands (%) 1.0 
?WBC (/μl) 1200 ?N Segmented (%) 25.0 
??Promyelocytes (%) 8.0 ?Eo (%) 0.0 
??N Myelocytes (%) 2.0 ?Ba (%) 0.0 
??N Metamyelocytes (%) 0.0 ?Lymphocytes (%) 52.0 
??N Band (%) 2.0 ?Monocytes (%) 2.0 
??N Segmented (%) 30.0 ?Histiocytes (%) 2.0 
??Eo (%) 1.0 ?Erythroblasts
??Ba (%) 0.0 ??Polyochromatic (%) 2.0 
??Lymphocytes (%) 54.0 ??Orthochromatic (%) 0.0 
??Monocytes (%) 1.0 
??Others (%) 2.0 Cytokines
?TNF-α (pg/ml)(<5) 1.3
PNH-type cells ?IFN-γ (IU/ml)(<0.1) 0.1
??G - ?Epo (mU/ml)(8-36) 24.8





Table 1 Laboratory data on admission
 PNH-type cells, G: granulocyte, E: erythrocyte Cytokine (?): normal value
Fig. 1  Hypocellular bone marrow at admis-
sion (x10).
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moglobunuria (PNH)-type cells measured 
by flow cytometry were not detected in the 
red cells and granulocytes.13)14) Plasma levels 
of tumor necrosis factor-α (TNF-α), inter-
feron-γ (IFN-γ), and erythropoietin (Epo) were 
normal, and that of granulocyte colony-
stimulating factor (G-CSF) was elevated. The 
clinical course is shown in Fig. 2. The patient 
started treatment in early December 2008, 
consisting of anti-thymocyte globulin (ATG, 
Lymphoglobuline, Genzyme), cyclosporine 
(CyA), and granulocyte colony-stimulating 
factor (G-CSF).15? Surprisingly, an increase 
in the leukocyte count and dysplastic granu-
locytes was observed 3 days after starting 
treatment. The laboratory data at that time 
are shown in Table 2. A bone marrow aspira-
tion smear demonstrated markedly hyper-
cellular marrow (Fig. 3A) with hypergranu-
lated promyelocytes showing Auer rods and 
Fagott and dysplastic cells (Fig. 3B). Flow 
cytometric analysis demonstrated increased 
expressions of CD2, CD13, CD33, and CD56. 
Cytogenetic analysis of bone marrow cells 
CBC Bone Marrow Markedly Hypercellular
?RBC (x104/μl) 320 ?Myeloblasts (%) 13.4 
?Hb (g/dl) 10.0 ?Promyelocytes (%) 56.0 
?Ht (%) 30.6 ?N Myelocytes (%) 9.0 
?Ret (%) ?N Metamyelocytes (%) 2.0 
?Platelets (x104/μl) 3.2 ?N Band (%) 1.8 
?WBC (/μl) 17000 ?N Segmented (%) 2.6 
??Promyelocytes (%) 11.0 ?Eo (%) 0.2 
??N Myelocytes (%) 9.0 ?Ba (%) 0.0 
??N Metamyelocytes (%) 2.0 ?Lymphocytes (%) 5.0 
??N Band (%) 0.5 ?Monocyts (%) 1.6 
??N Segmented (%) 15.0 ?Histiocytes (%) 0.0 
??Eo (%) 0.0 ?Erythroblasts
??Ba (%) 0.0 ??Polyochromatic (%) 6.8 
??Lymphocytes (%) 1.5 ??Orthochromatic (%) 1.4 
??Monocytes (%) 6.0 
??Others (%) 54.5 Chromosome
?46,XY,t(15;17)(q22;q12) 20/20
Hemostatic Study ?FISH,PML-RARα(%) 93
?PT (sec) 12.7 ?PML-RARα m-RNA +
?APTT (sec) 24.1 
?Fibrinogen (mg/dl) 106.0 Flow Cytometry
?FDP (μg/ml) 22.2 ?CD2 (%) 86.3
?D-dimer (μg/ml) 11.1 ?CD13 (%) 56.9
?SFMC (-) 1+ ?CD33 (%) 93.5
?TAT (ng/mL)(<3.0) 11.1 ?CD56 (%) 70.4
?PIC (μg/mL)(<0.8) 4.5 
Table 2 Laboratory data at diagnosis of APL
 Hemostatic study (?): normal value
Fig. 2  Clinical course.
  Ara-C: cytosine arabinoside, MIT: mi-
toxantrone, DNR: daunorubicin, IDA: 
idarubicin
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demonstrated t(15;17)(q22;q12) by G-banding, 
fusion signals of promyleocytic leukemia/
retinoic acid receptor-α (PML/RAR-α) genes 
by interphase fluorescence in situ-hybridiza-
tion (FISH), and chimeric PML/RAR-α fusion 
m-RNA by nested PCR. Laboratory data for 
disseminated intravascular coagulation (DIC) 
were observed. Acute promyelocytic leukemia 
(APL), M3 based on the French-American-
British (FAB) classification, was diagnosed. 
The treatment for AA was interrupted 3 days 
after commencing therapy. Leukopenia and 
bone marrow hypocellularity returned to the 
same levels as before the start of AA treat-
ment in early January 2009. Subsequently, 
treatment for APL was performed according 
to the Japan Adult Leukemia Study Group 
(JALSG), APL 204 protocol. Initially, all-
trans retinoic acid (ATRA), at 45 mg/m2/
day, was administered. Anemia and throm-
bocytopenia improved but recovery from 
leukopenia was insufficient. Leukocytosis or 
ATRA differentiation syndrome were not 
observed. A bone marrow aspiration smear 
revealed the disappearance of promyelocytes 
from the peripheral blood and bone marrow; 
however, it demonstrated hypocellular and 
dysplastic granulocytes with bi-nucleated 
or reniform nuclei, and erythroblasts with 
intercellular bridges were observed (Fig. 4). 
FISH analysis revealed a decrease in the fu-
sion signal of PML/RAR-α genes in 16% after 
40 days of ATRA treatment, and finally com-
pletely disappeared 60 days after the start of 
treatment. A bone marrow aspiration smear 
demonstrated a decrease of dysplastic cells; 
however, hypocellularity remained. Subse-
quently, 3 courses of consolidation chemo-
therapy consisting of cytosine arabinoside 
(Ara-C) and alternating regimens of mitox-
antrone (MIT), daunorubicin (DNR), and ida-
rubicin (IDR) as consolidation chemotherapy 
were performed with reduced doses of chemo-
therapeutic agents. During and after these 
treatments, severe pancytopenia recovered; 
Hb recovered and the platelet count markedly 
rose above normal. The recovery of neutro-
phils was delayed, although it finally recov-
ered; however, the bone marrow remained 
Fig. 3A  Hypercellular marrow at diagnosis 
of APL (x10).
Fig. 3B  Increased hypergranulated promy-
elocytes and dyslobulated granulo-
cytes (x100).
Fig. 4  Dysplastic cells after treatment of 
ATRA. Bi-nucleated granulocytes 
and erythroblasts with intercellular 
bridges (x100).
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hypocellular. Quantitative measurement of 
chimeric PML/RAR-α fusion m-RNA showed 
a decrease to undetectable levels. The patient 
was discharged, and will subsequently be 
treated with ATRA.
Discussion
 Typical AA is usually distinct from typi-
cal MDS and leukemia with respect to pan-
cytopenia and BM hypocellularity. However, 
clonal hematopoiesis was demonstrated in 
AA.???? The development of MDS/AML oc-
curs in 5 to 15% of long-term survivors with 
AA.???? There are also the concepts of hy-
poplastic MDS and leukemia,??10? and these 
disorders frequently evolve into AML.??10? 
Cytogenetic abnormalities such as monosomy 
7 or trisomy 8 are not informative for the 
differential diagnosis of these disorders, and 
the results are not informative in AA since 
a sufficient number of metaphase cells is dif-
ficult to obtain in this disorder.11? Thus, there 
are overlapping aspects among AA, MDS, 
and AML regarding the morphology and 
pathogenesis.??10? Thus, it may be sometimes 
difficult to differentiate MDS from AA, and 
some patients with MDS or hypoplastic leu-
kemia may be inadvertently included among 
those with a diagnosis of AA, especially in 
patients with pancytopenia and hypocellu-
lar bone marrow. The present patient was 
initially diagnosed with AA based on pnacy-
topenia, an extremely hypocellular marrow, 
and MRI findings, although PNH-type cells 
suggestive of immunologically mediated AA 
were negative in granulocytes and red cells. 
Repeated examinations involving bone mar-
row aspiration or bone marrow biopsy were 
not performed.
 However, the leukocyte count increased 
and bone marrow became extremely hy-
percellular shortly after the start of treat-
ment for AA, demonstrating an increase in 
promyelocytes and dysplastic granulocytes, 
responding to the administration of G-CSF. 
Documeneted infection was not observed af-
ter the treatment for AA. Retrospectively 
considered, low percentages of myeloblasts 
and hypergranulated promyelocytes were ob-
served in the peripheral blood and bone mar-
row aspiration smear at the diagnosis of AA, 
although lymphocytes were predominant 
and hypocellularity of the bone marrow was 
marked. The increase in the leukocyte count 
and hypercellular bone marrow returned to 
the pretreatment hypocellular state seen be-
fore treatment shortly after the cessation of 
AA treatment. The cytogenetic analysis of 
an increase in promyelocytes confirmed the 
diagnosis of APL. G-CSF administered for 
the treatment of AA might have stimulated 
the proliferation of APL cells. 
 Treatment by ATRA only successfully 
brought about hematological and cytogenetic 
responses. Any beneficial effect of G-CSF on 
ATRA treatment, if present, is unknown. It 
might be potentially effective for the treat-
ment of APL, tageting the leukemic cells 
entering the cell cycle and making them 
susceptible to differentiation into mature 
neutrophils by ATRA. However, the recov-
ery of neutrophils in peripheral blood was 
delayed, although they finally recovered, 
dysplastic granulocytes in the bone marrow 
remained for a period, and the bone mar-
row remained hypocellular. The dysplatic 
granulocytes with bi-nuceated or reniform 
nuclei may represent unique morphological 
characteristics, as observed in the micro-
granular variant of APL (M3v, based on FAB 
classification)12?, differentiation of blood cells 
by ATRA, and therapy-related APL treated 
with ATRA with or without chemotherapeu-
tic agents.16?18? ATRA used solely could bring 
about a complete hematological and cytoge-
netic remission. However, ATRA alone usu-
ally cannot achieve durable remission.12?19? So, 
the present patient was subsequently treated 
with consolidation chemotherapy. Peripheral 
blood Hb recovered, and the platelet count 
markedly recovered above normal, which 
is observed in the treatment of APL after 
treatments with ATRA and chemotherapy20?; 
however, the recovery of neutrophils was 
delayed although they finally recovered and 
bone marrow cellularity remained hypocel-
lular throughout the clinical course, even 
after complete hematological and cytogenetic 
responses were obtained. 
 The reason for the hypocellularity of bone 
marrow in APL remains unknown. Impaired 
hematopoiesis may have a clonal nature in-
volving multipotent hematopoietic stem cells 
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including leukemic stem and granulocyte-
committed stem cells.????21? APL cells them-
selves, or the cytokines such as leukemia 
inhibitory factor (LIF), TNF-α, or IFN-γ se-
creted by microenvironmental cells might in-
hibit hematopoiesis. TNF-α or IFN-γ was not 
increased and G-CSF was slightly elevated, 
while Epo was normal. These results are in-
consistent with a diagnosis of AA in which 
these cytokines are elevated, but are compat-
ible with APL in which G-CSF stimulates 
the proliferation and differentiation of pro-
myelocytes.22? The cytogenetically abnormal 
clone might affect impaired hematopoiesis. A 
rare case of hypocellular APL with a tetra-
ploid clone characterized by two t(15;17) was 
reported;23? however, this karyotypic abnor-
mality, or an additional abnormality such as 
-7 or +8 which is observed in AA, hypoplastic 
MDS, or leukemia11? was not observed in the 
present patient. The dysplastic cells observed 
might represent the clonal nature of im-
paired hematopoiesis. The expression of CD2 
and CD56 in addition to CD13 and CD33 is 
more frequently observed in M3v with micro-
granules with a poorer prognosis than in M3 
with hypergranules in APL; however, mar-
row hypocellularity was mentioned,24? and the 
present patient exhibited hypergranulated 
promyelocytes of M3.
 These results require further analysis re-
garding the significance of bone marrow hy-
pocellularity in APL in respect of pathophys-
iology and treatment.
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